Sex (male, n)
|
11(65%)
|
27(87%)
|
0.611
|
0.144—2.596
|
0.502
|
Age (y) (mean ± SD)
|
62.71 ± 16.34
|
57.61 ± 14.78
| | |
0.306
|
Co- morbidities
|
Diabetes mellitus
|
5 (29%)
|
9 (29%)
|
0.982
|
0.268—3.602
|
0.978
|
Hypertension
|
9 (53%)
|
15 (48%)
|
0.833
|
0.255—2.724
|
0.763
|
Coronary heart disease
|
1 (6%)
|
3 (10%)
|
1.714
|
0.164—17.886
|
1
|
Chronic liver disease
|
3(18%)
|
6(19%)
|
1.120
|
0.242–5.186
|
1
|
Chronic renal failure
|
2 (12%)
|
4 (13%)
|
1.111
|
0.182—6.796
|
0.909
|
Solid organ tumor
|
4 (24%)
|
7 (23%)
|
0.948
|
0.233—3.850
|
0.940
|
HIV
|
0
|
0
|
NA
|
NA
|
NA
|
Surgery in the past medical historya
|
3 (18%)
|
5 (16%)
|
0.897
|
0.186—4.322
|
0.893
|
Prior healthcare-associated exposure
|
7 (41%)
|
9 (29%)
|
0.584
|
0.169—2.017
|
0.393
|
Prior medicine exposure
|
Glucocorticoid
|
7 (41%)
|
13 (42%)
|
1.032
|
0.311—3.428
|
0.959
|
Immunosuppressorb
|
1 (6%)
|
2 (6%)
|
1.103
|
0.093—13.135
|
1
|
Prior use of antimicrobials
|
Penicillin
|
3 (18%)
|
10 (32%)
|
2.105
|
0.480—9.237
|
0.318
|
Second cephalosporin
|
1 (6%)
|
4 (13%)
|
2.240
|
0.228—22.051
|
0.838
|
extended-spectrum cephalosporins
|
7 (41%)
|
15 (48%)
|
1.224
|
0.351—4.269
|
0.750
|
Aminoglycosides
|
1 (6%)
|
3 (10%)
|
1.615
|
0.153—17.016
|
1
|
Quinolones
|
1 (6%)
|
3 (10%)
|
1.615
|
0.153—17.016
|
1
|
Tigecycline
|
0
|
4 (13%)
|
0.625
|
0.492—0.795
|
0.613
|
Imipenem
|
1 (6%)
|
11(39%)
|
8.556
|
0.984—74.408
|
0.064
|
Meropenem
|
1 (6%)
|
12 (39%)
|
9.882
|
1.141—85.619
|
0.068
|
Ertapenem
|
0
|
0
|
NA
|
NA
|
NA
|
Linezolid
|
1 (6%)
|
12 (39%)
|
9.882
|
1.141—85.619
|
0.068
|
Glycopeptides Vancomycin
|
1 (6%)
|
8 (26%)
|
5.333
|
0.599—47.468
|
0.216
|
Teicoplanin
|
1 (6%)
|
5 (16%)
|
2.917
|
0.309—27.560
|
0.333
|
Invasive procedure before
|
Central venous catheterization
|
10(59%)
|
30 (97%)
|
21.000
|
2.294—192.225
|
0.003
|
Trachea cannula
|
4(24%)
|
10 (32%)
|
1.548
|
0.401—5.971
|
0.525
|
Tracheotomy
|
5(29%)
|
12 (39%)
|
1.516
|
0.426—5.393
|
0.519
|
Urinary catheter
|
7(41%)
|
23 (74%)
|
4.107
|
1.168—14.436
|
0.024
|
stomach tube
|
14(82%)
|
27 (87%)
|
1.446
|
0.283—7.384
|
0.656
|
Intrathoracic drain
|
0(0)
|
4 (13%)
|
0.614
|
0.485—0.776
|
0.282
|
Abdominal cavity drainage-tube
|
5(29%)
|
15 (48%)
|
2.250
|
0.639—7.923
|
0.202
|
External ventricular drainage tube care
|
0(0)
|
1 (3%)
|
0.612
|
0.490—0.765
|
1
|
Liver function on admission
|
5(35%)
|
3 (10%)
|
0.257
|
0.053—1.252
|
0.079
|
Renal function on admission
|
7(41%)
|
4(13%)
|
0.275
|
0.071—1.070
|
0.055
|
APACHE II score on admission
|
12.29 ± 7.32
|
9.45 ± 4.60
| | |
0.334
|